These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8574163)

  • 1. VAD-cyclosporine therapy for VAD-resistant multiple myeloma.
    Weber D; Dimopoulos M; Sinicrope F; Alexanian R
    Leuk Lymphoma; 1995 Sep; 19(1-2):159-63. PubMed ID: 8574163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).
    Sonneveld P; Suciu S; Weijermans P; Beksac M; Neuwirtova R; Solbu G; Lokhorst H; van der Lelie J; Dohner H; Gerhartz H; Segeren CM; Willemze R; Lowenberg B; ; ;
    Br J Haematol; 2001 Dec; 115(4):895-902. PubMed ID: 11843823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON.
    Sonneveld P; Durie BG; Lokhorst HM; Marie JP; Solbu G; Suciu S; Zittoun R; Löwenberg B; Nooter K
    Lancet; 1992 Aug; 340(8814):255-9. PubMed ID: 1353189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
    Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
    Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
    Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study.
    Dalton WS; Crowley JJ; Salmon SS; Grogan TM; Laufman LR; Weiss GR; Bonnet JD
    Cancer; 1995 Feb; 75(3):815-20. PubMed ID: 7828131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells.
    Sonneveld P; Schoester M; de Leeuw K
    J Clin Oncol; 1994 Aug; 12(8):1584-91. PubMed ID: 7518859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma.
    Dimopoulos MA; Pouli A; Zervas K; Grigoraki V; Symeonidis A; Repoussis P; Mitsouli C; Papanastasiou C; Margaritis D; Tokmaktsis A; Katodritou I; Kokkini G; Terpos E; Vyniou N; Tzilianos M; Chatzivassili A; Kyrtsonis MC; Panayiotidis P; Maniatis A;
    Ann Oncol; 2003 Jul; 14(7):1039-44. PubMed ID: 12853344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group.
    Friedenberg WR; Rue M; Blood EA; Dalton WS; Shustik C; Larson RA; Sonneveld P; Greipp PR
    Cancer; 2006 Feb; 106(4):830-8. PubMed ID: 16419071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD).
    Adam Z; Elbl L; Vorlicek J; Hájek R; Hájek D; Hejlová N; Králová E; Novotná H
    Acta Med Austriaca; 1994; 21(4):111-5. PubMed ID: 7871966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
    Dalton WS; Grogan TM; Meltzer PS; Scheper RJ; Durie BG; Taylor CW; Miller TP; Salmon SE
    J Clin Oncol; 1989 Apr; 7(4):415-24. PubMed ID: 2564428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.
    Rifkin RM; Gregory SA; Mohrbacher A; Hussein MA
    Cancer; 2006 Feb; 106(4):848-58. PubMed ID: 16404741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group.
    Browman GP; Belch A; Skillings J; Wilson K; Bergsagel D; Johnston D; Pater JL
    Br J Haematol; 1992 Nov; 82(3):555-9. PubMed ID: 1486035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study.
    Gertz MA; Kalish LA; Kyle RA; Hahn RG; Tormey DC; Oken MM
    Am J Clin Oncol; 1995 Dec; 18(6):475-80. PubMed ID: 8526187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents.
    Cornelissen JJ; Sonneveld P; Schoester M; Raaijmakers HG; Nieuwenhuis HK; Dekker AW; Lokhorst HM
    J Clin Oncol; 1994 Jan; 12(1):115-9. PubMed ID: 7903690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VAD regimen in the treatment of resistant multiple myeloma: slow or fast infusion?
    Koskela K; Pelliniemi TT; Remes K
    Leuk Lymphoma; 1993 Jul; 10(4-5):347-51. PubMed ID: 8220133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/dexamethasone in patients with newly diagnosed multiple myeloma.
    Porter CA; Rifkin RM
    Clin Lymphoma Myeloma; 2007 Apr; 7 Suppl 4():S150-5. PubMed ID: 17562253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.
    Segeren CM; Sonneveld P; van der Holt B; Baars JW; Biesma DH; Cornellissen JJ; Croockewit AJ; Dekker AW; Fibbe WE; Löwenberg B; van Marwijk Kooy M; van Oers MH; Richel DJ; Schouten HC; Vellenga E; Verhoef GE; Wijermans PW; Wittebol S; Lokhorst HM
    Br J Haematol; 1999 Apr; 105(1):127-30. PubMed ID: 10233375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of refractory multiple myeloma with the vincristine-adriamycin-dexamethasone (VAD) regimen.
    Stenzinger W; Blömker A; Hiddemann W; van de Loo J
    Blut; 1990; 61(2-3):55-9. PubMed ID: 2207342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bolus vincristine and epirubicin with cyclophosphamide and dexamethasone (VECD) as induction and salvage treatment in multiple myeloma.
    Fosså A; Muer M; Kasper C; Welt A; Seeber S; Nowrousian MR
    Leukemia; 1998 Mar; 12(3):422-6. PubMed ID: 9529138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.